Actively Recruiting
Study of SGLT2 Inhibitor Effects on Kidney and Metabolism in Patients 65 and Older
Led by Chiara Lanzani · Updated on 2025-08-13
300
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying how SGLT2 inhibitor therapy affects elderly patients, focusing on both kidney and metabolic aspects. This observational project combines clinical and biological data and uses advanced Bayesian statistics to explore how risk factors relate to patient outcomes after treatment with SGLT2 inhibitors. The study aims to better understand the effects of these drugs in people aged 65 and older with various conditions like diabetes, heart, and kidney diseases. Participants are patients aged 65 or older who have been prescribed an SGLT2 inhibitor for any clinical reason and have not yet started this therapy. The study observes these patients from the time of prescription and tracks their health status over six months of treatment. There are no experimental interventions since the therapy is given as part of routine care following clinical guidelines. During the study, researchers will assess patient health before and after six months of treatment using the Frailty Index to measure changes in overall health status. Participants will provide clinical and biological information over this period, allowing detailed monitoring of treatment effects. The study begins in February 2025 and continues until February 2027, focusing on real-world outcomes in elderly patients receiving SGLT2 inhibitors.
CONDITIONS
Brief Title
Multidisciplinary Dissection of Renal and Metabolic Effects of Glyfozines on Elderly Patients: From Molecular Aspects to Clinical Indications
Research Team
C
Chiara Livia Lanzani, professor
F
Federica Guerra, Dr
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here